 Recent phase 2b tuberculosis vaccine trials have shown promising results in adolescents and adults. Despite this, experience in vaccinating these age groups is limited. To explore possible implementation strategies, we interviewed key decision makers from South Africa, India and China. They expressed interest in novel TB vaccines, naming school attending adolescents and older people as potential targets. They favored routine vaccination over targeted mass campaigns due to stigma and logistical difficulties. The two-dose regimen of M72-AS01E was seen as a challenge, particularly in South Africa, where many people are living with HIV. Challenges and opportunities were identified in all three countries. This study provides valuable insight into the acceptability and feasibility of novel TB vaccines in specific target groups and countries. This article was authored by Pakti Pelser, Janet Sealy, Fiona Yuchien Sun and others.